| Baylor Research Institute Patent applications |
| Patent application number | Title | Published |
|---|
| 20120128710 | Enhancement of Pathogen-Specific Memory Th17 Cell Responses - Compositions and methods for enhancing Th1/Th17 cell responses and decreasing Th2 cell responses are disclosed herein. In various embodiments the present invention describes activation of human dendritic cells and enhancement of antigen-specific T cell responses in a Dectin-1-expressing human dendritic cells comprising an anti-Dectin-1-specific antibody or fragment thereof fused with one or more antigens. TLR2 ligands may also be included to enhance the activation and for enhancement of T-cell responses. Further, the invention also includes methods based on the compositions described herein for the treatment of pathogenic infections. | 05-24-2012 |
| 20120121592 | Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells - Compositions and methods for targeting protein antigens to human DCs via DC-asialoglycoprotein receptor (DC-ASGPR) are disclosed herein. The DC-ASGPR carries an intracellular tyrosine-based and dileucine motif, resulting in the generation of such IL-10 Tregs both in vitro and in vivo. The methods of the present invention can be used for designing vaccines against autoimmune diseases where autoantigens are defined, such as type 1 diabetes and multiple sclerosis. | 05-17-2012 |
| 20120088687 | MicroRNAs (miRNA) as Biomarkers for the Identification of Familial and Non-Familial Colorectal Cancer - A technique for the analysis of global miRNA signatures including a larger panel of miRNAs in various groups of well-characterized colorectal cancers (CRCs) is described in the instant invention. The results presented herein provide a large list of miRNAs that are dysregulated in CRC compared to the normal colonic tissue, and, more importantly, the present invention shows for the first time that Lynch syndrome and sporadic MSI tumors exhibit a different miRNA signature that distinguishes them. | 04-12-2012 |
| 20120039916 | NOVEL VACCINE ADJUVANTS BASED ON TARGETING ADJUVANTS TO ANTIBODIES DIRECTLY TO ANTIGEN-PRESENTING CELLS - Compositions and methods for enhancing an immune response with an adjuvant composition comprising: an anti-dendritic cell (DC)-specific antibody or fragment thereof conjugated to at least a portion of a TLR agonist; and a pharmaceutically acceptable carrier are disclosed herein. The conjugate and agonist are each comprised in an amount such that, in combination with the other, are effective to produce the immune response in a human or animal subject in need of immunostimulation. | 02-16-2012 |
| 20120027674 | IL-18 RECEPTOR AS A NOVEL TARGET OF REGULATORY T CELLS IN CANCER - Compositions and methods for use in preventing, inhibiting or reducing tumor cell growth comprising an effective amount of an active agent that kills IL-18 Receptor expressing T cells in admixture with a suitable diluent or carrier are described herein. | 02-02-2012 |
| 20120020963 | ANTI-INTEFERON ALPHA MONOCLONAL ANTIBODIES AND METHODS FOR USE - The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease. | 01-26-2012 |
| 20120020960 | Thymic Stromal Lymphopoietin (TSLP) and OX40 Ligand in Cancer - Compositions and methods for an immunotherapeutic approach for human breast cancer is provided herein. Any antagonist of thymic stromal lymphopoietin (TSLP) and/or OX40L to inhibit tumor development and IL-13 secretion by blocking the upregulation of OX40L by DCs exposed to breast cancer, thereby blocking their capacity to generate inflammatory IL-13 | 01-26-2012 |
| 20120009244 | NEUROD1 GENE EXPRESSION IN NON-ENDOCRINE PANCREATIC EPITHELIAL CELLS (NEPECs) - The introduction of the human NeuroD1 gene into human non-endocrine pancreatic epithelial cells (NEPECs) for producing insulin producing cells in vitro is described herein. Cytokeratin19 (CK19) positive NEPECs were transfected with plasmids encoding human NeuroD1 gene under human CK19 promoter. On characterization following the induction it was found that NEPEC+ND strongly expressed NeuroD1 and insulin mRNA. The ratio of NeuroD1 and human insulin positive cells in NEPEC+ND was significantly higher than NEPEC. Human insulin and C-peptide levels in culture media in NEPEC+ND were significantly higher than NEPEC. The findings demonstrate that human NeuroD1 under control of the CK19 promoter induces the differentiation of CK19 positive NEPECs into insulin producing cells. | 01-12-2012 |
| 20120004643 | Vaccines Based on Targeting Antigen to DCIR Expressed on Antigen-Presenting Cells - The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex. | 01-05-2012 |
| 20110312521 | Genomic Transcriptional Analysis as a Tool for Identification of Pathogenic Diseases - The discovery and validation of a candidate biomarker signature for the diagnosis of sepsis, and more particularly septicemic meliodiosis, based on genomic transcriptional profiling using microarrays is described herein. The microarray technology of the instant invention generates genome-wide transcriptional profiles (>48,000 transcripts) from the whole blood of patients with septicemic melioidosis (n=32), patients with sepsis caused by other pathogens (n=31), and uninfected controls (n=29). Unsupervised analyses demonstrated the existence of a whole blood transcriptional signature distinguishing patients with sepsis from control subjects. | 12-22-2011 |
| 20110306663 | TRIHEPTANOIN DIET FOR ADULT POLYGLUCOSAN BODY DISEASE (APBD) TREATMENT - Compositions and methods for the treatment and management of adult polyglucosan body disease (APBD) are disclosed herein. The APBD patients studied in the present invention experienced stabilization of disease progression and limited functional improvement with dietary triheptanoin (C7TG). The amount of C7TG administered to the patient daily for 6-8 months was 1-2 g/kg/24 hrs. The present invention demonstrates, for the first time, the arrest of clinical deterioration with limited functional recovery in APBD with triheptanoin diet therapy. | 12-15-2011 |
| 20110305719 | Inhibition of Pro-Inflammatory Cytokine Induced Response - Method and compositions for reducing the inflammation after cytokine exposure of an islet cell transplant without affecting the viability and potency are disclosed herein. The present invention describes a composition comprising Withaferin A (WA), a steroidal lactone derived from | 12-15-2011 |
| 20110274653 | DENDRITIC CELL IMMUNORECEPTORS (DCIR)-MEDIATED CROSSPRIMING OF HUMAN CD8+ T CELLS - Immunostimulatory compositions and methods comprising an ITIM motif-containing DC immunoreceptor (DCIR) to mediate potent crosspresentation are described herein. The inventors evaluated human CD8+ T cell responses generated by targeting antigens to dendritic cells (DCs) through various lectin receptors. A single exposure to a low dose of anti-DCIR-antigen conjugate initiated antigen-specific CD8+ T cell immunity by all human DC subsets including ex vivo generated DCs, skin-isolated Langerhans cells and blood mDCs and pDCs. Enhanced specific CD8+ T cell responses were observed when antigens like, FluMP, MART-1, viral (HIV gag), etc. were delivered to the DCs via DCIR, compared to those induced by a free antigen, or antigen conjugated to a control mAb or delivered via DC-SIGN, another lectin receptor. Addition of Toll-like receptor (TLR) 7/8-agonist enhanced DCIR-mediated crosspresentation as well as crosspriming. Thus, antigen targeting via the human DCIR receptor allows activation of specific CD8+ T cell immunity. | 11-10-2011 |
| 20110268767 | USE OF ALLOGENEIC CELL LINES TO LOAD ANTIGEN-PRESENTING CELLS TO ELICIT OR ELIMINATE IMMUNE RESPONSES - Novel antigen-presenting cells, including but not limited to dendritic cells, that are loaded with antigens from dead or dying cells including allogenic cell lines, and the methods for making such antigen-presenting cells are described. These loaded antigen-presenting cells induce therapeutic immune responses in humans. Such loaded antigen-presenting cells are useful in the management of cancer. Antigen-loaded dendritic cells prepared as described here can prime naïve T cells to differentiate into effector cells able to recognize multiple and/or shared tumor antigens that are expressed either on the tumor cells that are used to load the dendritic cells and/or on other tumor cells. The cytotoxic T cells generated by exposure to antigen-loaded dendritic cells prepared as described here can be used in adoptive therapy. This induction of responses against multiple antigens shared between different cells, for instance tumor cells, as described here is important as it leads to broad immune responses. | 11-03-2011 |
| 20110217288 | Involvement of Androgen/Androgen Receptor Pathway in Fabry Disease - Novel therapies for the treatment of Fabry disease by using androgen/androgen receptor (AR) pathway-related molecules as biomarkers and use of approaches targeting androgen/AR pathway are presented herein. The involvement of aberrant androgen/AR pathway in Fabry disease has never been previously described. The present invention describes, (i) use of approaches that target androgen/AR pathway as therapeutic treatments for Fabry disease and (2) use of the levels of androgen/AR pathway-related molecules in body fluids or tissues as biomarkers for evaluation of disease progression and efficacy of treatments in Fabry patients. | 09-08-2011 |
| 20110201558 | Anaplerotic Therapy for Alzheimer's Disease and the Aging Brain - The present invention describes methods and compositions for the treatment of neurodegenerative conditions including Alzheimer's disease (AD) and aging. The present invention discloses an anaplerotic diet therapy for the treatment of AD. The high fat, low carbohydrate diet described in the various embodiments of the present invention increasing circulating ketone bodies, reduces amyloid-β (Aβ) deposition in AD patients, thereby improving cognition and locomotive skills. | 08-18-2011 |
| 20110196614 | BLOOD TRANSCRIPTIONAL SIGNATURE OF MYCOBACTERIUM TUBERCULOSIS INFECTION - The present invention includes methods, systems and kits for distinguishing between active and latent | 08-11-2011 |
| 20110182979 | In-Vivo Non-Viral Gene Delivery of Human Vascular Endothelial Growth Factor Following Islet Transplantation - An ultrasound-mediated gene transfer method named Ultrasound Targeted Microbubble Destruction (UTMD) for the delivery of human vascular endothelial growth factor (hVEGF) gene to transplanted islets and the surrounding tissue is described herein. The delivery of hVEGF promotes islet revascularization and survival. The inventors, first transplanted human islets were transplanted into diabetic nude mice liver followed by the induction of non-viral plasmid vectors encoding hVEGF or Green Fluorescent Protein (GFP) gene in the host liver by UTMD. Transplantation without gene delivery was also performed as a control. Blood glucose, serum human insulin, C-peptide levels and the revascularization in graft islets were evaluated. The findings of the method of the present invention indicated that hVEGF gene delivery to host liver using UTMD promoted islet revascularization after islet transplantation and improved the restoration of euglycemia. | 07-28-2011 |
| 20110182937 | Dendritic Cell Vaccines - Compositions and methods for the prophylaxis and treatment of human immunodeficiency virus (HIV) infections are disclosed herein. More specifically the present invention discloses describes an autologous dendritic cell (DC) vaccine product derived by culturing a patient's monocytes with granulocyte macrophage colony stimulating factor (GM-CSF) and interferon alpha 2b (IFN-α), loading the DC with a mixture of five lipopeptides of Gag, Nef and Pol HIV antigens, and, optionally activating the DC with lipopolysaccharide (LPS). | 07-28-2011 |
| 20110172271 | Urinary Triaosylceramide (GB3) as a Marker of Cardiac Disease - The present invention describes a method for determination of urinary globotriaosylceramide (Gb3) levels in non-Fabry disease cardiac patients. Determination of Gb3 levels provides a screening method for determining cardiac risk and may offer an alternative therapeutic option for cardiac disease management or cardiac disease risk mitigation by lowering Gb3 levels by the use of pharmacological chaperones or other agents. | 07-14-2011 |
| 20110129817 | BLOOD TRANSCRIPTIONAL SIGNATURE OF ACTIVE VERSUS LATENT MYCOBACTERIUM TUBERCULOSIS INFECTION - The present invention includes methods, systems and kits for distinguishing between active and latent | 06-02-2011 |
| 20110125144 | METHOD OF TREATING ATRIAL FIBRILLATION THROUGH EPICARDIAL LESION - A method of treating atrial fibrillation through minimal access ablation to form atrial lesions on the dome of the atrium. | 05-26-2011 |
| 20110112041 | Treatment of Male-Pattern Baldness by Local Induction of the Metabolic Defect of Fabry Disease - Compositions comprising inhibitors of lysosomal enzyme alpha-galactosidase A and their use to favor hair growth or to prevent hair loss are disclosed in the instant invention. The topical use of the composition of the instant invention directly inhibits scalp enzyme activity and is used in the treatment for male pattern baldness (androgenic alopecia) in men and women. | 05-12-2011 |
| 20110098677 | Functionalization of Micro- and Nano-Particles for Selective Attachment to Calcium Biomineral Surfaces - A seven-carbon fatty acid or derivative thereof has been identified as an excellent energy source for humans or human infants. A nutritional supplement suitable for humans or human infants comprising a seven carbon fatty acid chain compound or derivative thereof can be used to increase energy production derived from fatty acid metabolism. For example, administering a seven carbon fatty acid chain compound or derivative thereof can be used to accelerate the growth rate of a prematurely born human infant. | 04-28-2011 |
| 20110086353 | Identification of MicroRNAs (miRNAs) in Fecal Samples as Biomarkers for Gastroenterological Cancers - A simple, rapid, inexpensive, and promising commercial biomarker assay method for multiple diseases is described herein. The present invention detects miRNA-based biomarkers in human stool specimens. The method of the present invention amplifies miRNA directly from stool specimens without any prior miRNA extraction. Differential expression of specific microRNAs in stool of colorectal cancer CRC and adenoma patients suggest fecal microRNAs as a novel potential biomarker for colorectal neoplasia detection. The method of the present invention has diagnostic, prognostic, and therapeutic relevance for gastroenterological cancers/colorectal cancer and as well as further acquired or hereditary GI diseases. | 04-14-2011 |
| 20110081343 | VACCINES DIRECTED TO LANGERHANS CELLS - The present invention includes isolated anti-Langerin vaccines, methods for making and using an isolated anti-Langerin antibody or binding fragment thereof and one or more antigenic peptides at the carboxy-terminus of the isolated anti-Langerin antibody, wherein when two or more antigenic peptides are present, the peptides are separated by the one or more linker peptides that comprise at least one glycosylation site. The present invention also includes isolated vectors for the expression of the anti-Langerin antigen delivery vectors and their manufactures and use. | 04-07-2011 |
| 20100330115 | Multivariable Antigens Complexed with Targeting Humanized Monoclonal Antibody - The present invention includes compositions and methods for designing, making and using modular recombinant antibodies or fragments thereof with one half of a cohesin-dockerin pair that permits the rapid assembly of multivariant antigen conjugates. | 12-30-2010 |
| 20100322929 | ANTIGEN PRESENTING CELL TARGETED CANCER VACCINES - The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies. | 12-23-2010 |
| 20100297114 | ANTIGEN PRESENTING CELL TARGETED VACCINES - The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies. | 11-25-2010 |
| 20100291082 | ANTIGEN PRESENTING CELL TARGETED ANTI-VIRAL VACCINES - The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies. | 11-18-2010 |
| 20100260747 | Use of Tetrahydrobiopterin as a Marker and a Therapeutic Agent for Fabry Disease - Blood and tissue markers of the metabolic status, risk of health complications in Fabry disease patients and as a biomarker to follow the efficacy of treatment in animal models and patients with Fabry disease comprising tetrahydrobiopterin (BH4), precursors and metabolites of BH4, and other related co-factors is disclosed herein. The present invention further describes the use of BH4 therapy as a treatment option for Fabry disease to prevent, slow or reverses vascular cardiac and renal manifestations of Fabry disease. | 10-14-2010 |
| 20100239575 | ANTI-CD40 ANTIBODIES AND USES THEREOF - The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies. | 09-23-2010 |
| 20100222428 | Fatty Acid Nutritional Supplement - A seven-carbon fatty acid or derivative thereof has been identified as an excellent energy source for humans or human infants. A nutritional supplement suitable for humans or human infants comprising a seven carbon fatty acid chain compound or derivative thereof can be used to increase energy production derived from fatty acid metabolism. For example, administering a seven carbon fatty acid chain compound or derivative thereof can be used to accelerate the growth rate of a prematurely born human infant. | 09-02-2010 |
| 20100167259 | APPARATUS AND METHOD FOR THE PRESERVATION OF PANCREATIC TISSUE AND ISLET CELLS FOR TRANSPLANTATION - The present invention includes compositions and methods for the preparation, preservation and storage of organs (e.g., pancreatic islet cells) for transplantation by storing organs in which the organs are suspended in a solution for maintaining viability and the organ or cells are cooled in a refrigeration unit for the entire duration of storage in which the average temperature in the apparatus does not vary by more than 2 degrees centigrade from the set temperature. | 07-01-2010 |
| 20100166718 | LARGE SCALE PANCREATIC ISLET PURIFICATION - The present invention includes a method of isolating pancreatic islets by density centrifugation wherein the pancreatic islets are loaded in a solution comprising pancreatic islets with the density gradient and the islets are isolated by centrifuging the vessel wherein the pressure on the pancreatic islets is less than 50 Pa and wherein the pancreatic islets are isolated from the gradient, the improvement comprising creating a continuous density gradient in a vessel comprising at least 100 milliliters with a bend tube that reduces convection currents that disrupt the gradient. | 07-01-2010 |
| 20100135994 | HIV VACCINE BASED ON TARGETING MAXIMIZED GAG AND NEF TO DENDRITIC CELLS - The present invention includes compositions and methods for making and using a vaccine that includes a DC-specific antibody or fragment thereof to which an engineered Gag antigen is attached to form an antibody-antigen complex, wherein the Gag antigen is less susceptible to proteolytic degradation by eliminating one or more proteolytic sites or a DC-specific antibody or fragment thereof to which an engineered Nef antigen is attached to form an antibody-antigen complex, wherein the Nef antigen comprises one or more codon usage optimization that increase antibody-antigen complex secretion, or both, wherein the vaccine is able to elicit an HIV-specific T cell immune response to Gag p17, Gag p24, Nef and/or Cyclin D1. | 06-03-2010 |
| 20100113293 | SYSTEMIC LUPUS ERYTHEMATOSUS DIAGNOSTIC ASSAY - The present invention provides compositions and methods for aiding in the diagnosis, monitoring and prognosis of SLE in a subject and for identifying potential therapeutic agents to treat and/or ameliorate the symptoms associated with SLE. Accordingly, embodiments of the invention are directed to methods of identifying the gene expression profile of a suitable sample by screening for the presence of a differentially expressed SLE-associated gene isolated from a sample containing or suspected of containing a cell that can differentially express an SLE-associated gene. | 05-06-2010 |
| 20100076691 | Diagnosis of Metastatic Melanoma and Monitoring Indicators of Immunosuppression Through Blood Leukocyte Microarray Analysis - The present invention includes compositions, systems and methods for the early detection and consistent determination of metastatic melanoma and/or immunosuppression using microarrays by calculating one or more expression vectors from the expression of one or more genes. | 03-25-2010 |
| 20100069466 | Compositions and Methods for the Systemic Treatment of Arthritis - The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β. | 03-18-2010 |
| 20100068201 | COMPOSITIONS AND METHODS FOR THE SYSTEMIC TREATMENT OF ARTHRITIS - The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β. | 03-18-2010 |
| 20100061965 | RESPIRATORY SYNCYTIAL VIRUS RENDERS DENDRITIC CELLS TOLEROGENIC - The present invention includes compositions, methods and systems for inducing immune tolerance using antigen presenting cells by infecting isolated antigen presenting cells with an effective amount of respiratory syncytial virus (RSV) or portions thereof sufficient to infect the antigen presenting cells and contacting CD4 | 03-11-2010 |
| 20100056908 | SYSTEM AND METHOD FOR PRE-PLANNING A RADIATION TREATMENT - The present invention includes a method of pre-planning a spherical fixed point stereotactic radiosurgery by obtaining an image from a patient having a target, the image comprising coordinates of the actual patient target in 3 dimensions on a first day; planning an optimal stereotactic radiosurgery using the patient's actual target using actual coordinates in 3 dimensions prior to the day of surgery by creating virtual radiosurgical coordinates and plans to maximize target exposure and minimize the patient's waiting time in radiosurgery, thereby allowing evaluation of several plans to maximize plan conformality and safety; and treating the patient based on the virtual stereotactic radiosurgery plans on a second day. | 03-04-2010 |
| 20100041755 | FATTY ACID TREATMENT FOR CARDIAC PATIENTS - A method of treating patients in need of treatment for a cardiac disorder has been found which comprises administering to the patient a seven carbon fatty acid compound or derivative thereof, wherein the compound or derivative thereof is able to readily enter the mitochondrion without special transport enzymes. A dietary formulation suitable for treatment of heart tissue in cardiac or surgical patients has been found which comprises a seven-carbon fatty acid chain, wherein the seven-carbon fatty acid chain is characterized by the ability to transverse the inner mitochondrial membrane by a transport mechanism which does not require carnitine palmitoyltransferase I, carnitine palmitoyltransferase II, or carnitine/acylcarnitine translocase and the ability to undergo mitochondrial β-oxidation, and wherein the compound is selected from the group consisting of n-heptanoic acid or a derivative thereof, a triglyceride comprising n-heptanoic acid or a derivative thereof, and triheptanoin or a derivative thereof. | 02-18-2010 |
| 20090304659 | ANTI-CD8 ANTIBODIES BLOCK PRIMING OF CYTOTOXIC EFFECTORS AND LEAD TO GENERATION OF REGULATORY CD8+ T CELLS - The present invention includes compositions and methods for inducing tolerance in a subject in need thereof comprising providing the subject with an effective amount of an anti-CD8 antibody sufficient in induce CD8 | 12-10-2009 |
| 20090191608 | Pancreatic Islet Cell Preparation and Transplantation - The present invention includes compositions and methods for the preparation of pancreatic islet cells for transplantation. | 07-30-2009 |
| 20090076131 | Anti-Cancer and Anti-Inflammatory Effects of Annurca Apple Extracts and Compositions Purified Therefrom - The present invention includes compositions and methods for modulating cell proliferation using a pharmaceutical effective amount of an isolated and purified polyphenolic composition having one or more polyphenolic compounds extracted from one or more plant tissues, specifically from one or more tissues of the Annurca apple. | 03-19-2009 |
| 20080286314 | Dendritic cells loaded with heat shocked melanoma cell bodies - The present invention includes compositions and methods for the isolation, purification and preparation of immunogenic antigens for the production of customized cancer vaccines that include dendritic cells that are contacted with an antigen that includes heat-shocked cancer cells. | 11-20-2008 |
| 20080267984 | Activation of Human Antigen-Presenting Cells Through Dendritic Cell Lectin-Like Oxidized LDL Receptor-1 (LOX-1) - The present invention includes compositions and methods for targeting the LOX-1 receptor on immune cells and uses for the anti-LOX-1 antibodies. | 10-30-2008 |
| 20080254047 | Activation of Human Antigen-Presenting Cells Through CLEC-6 - The present invention includes compositions and methods for using novel anti-CLEC-6 antibodies and fragments thereof for modulating the activity of immune cells. | 10-16-2008 |
| 20080254044 | Multivariable Antigens Complexed with Targeting Humanized Monoclonal Antibody - The present invention includes compositions and methods for designing, making and using modular recombinant antibodies or fragments thereof with one half of a cohesin-dockerin pair that permits the rapid assembly of multivariant antigen conjugates. | 10-16-2008 |
| 20080241170 | Vaccines Based on Targeting Antigen to DCIR Expressed on Antigen-Presenting Cells - The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex. | 10-02-2008 |
| 20080233140 | Therapeutic Applications of Activation of Human Antigen-Presenting Cells Through Dectin-1 - The present invention includes compositions and methods for binding Dectin-1 on immune cells with anti-Dectin-1-specific antibodies or fragment thereof capable of activating the immune cells. | 09-25-2008 |
| 20080227709 | GENE EXPRESSION IN PERIPHERAL BLOOD MONONUCLEAR CELLS FROM CHILDREN WITH DIABETES - The present invention includes composition, methods and systems for detecting, evaluating, diagnosis, tracking and treating Type 1 Diabetes by determining the level of expression of one or more genes listed in Table 1 (e.g., interleukin-1β (IL1B), early growth response gene 3 (EGR3), and prostaglandin-endoperoxide synthase 2 (PTGS2)). The present invention also includes compositions and methods for treating a patient in need thereof with a composition having a therapeutically effective amount of one or more IL-1β antagonists sufficient to spare pancreatic beta cells, including an anti-IL-1β receptor and downstream activators. | 09-18-2008 |
| 20080206262 | Agents That Engage Antigen-Presenting Cells Through Dendritic Cell Asialoglycoprotein Receptor (DC-ASGPR) - The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells. | 08-28-2008 |
